Abstract Background Fibroblast growth factor (FGF23) is a phosphate-regulating hormone and might be a biomarker of cardiorenal comorbidities in the general population. Its role in hypoparathyroidism is unclear. Objective To assess prevalence of abnormal FGF23 concentrations in patients with chronic hypoparathyroidism and explore their associations with mineral metabolism and renal phosphate handling. Design Cross-sectional, observational study complemented by a retrospective longitudinal analysis of biochemical parameters over a median follow-up of 5 years. Patients Forty-eight consecutive patients with chronic hypoparathyroidism (mean age 60.6±16.3 years; 85% women; 87.5% postsurgical) evaluated at an academic medical center between January 2023 and December 2024. Measurements Serum intact FGF23 levels, serum calcium and phosphate, Ca×P product, PTH, 1,25(OH)₂ vitamin D, eGFR, and renal phosphate reabsorption (TmPO₄/GFR). Results Elevated FGF23 levels were found in 71% of patients (mean 157.9±92.4 pg/mL; reference range 23.2–95.4), despite adequate biochemical control (calcium 8.7±0.8 mg/dL; phosphate 4.5±0.8 mg/dL; Ca×P product 39.2±6.8 mg²/dL²). FGF23 was associated with longer disease duration (p=0.004), lower eGFR (p=0.008), lower PTH (p=0.03), reduced 1,25(OH)₂D (p=0.016), and elevated Ca×P product (p=0.036). Despite elevated FGF23, TmPO₄/GFR was paradoxically increased, suggesting impaired renal responsiveness. Female sex and Ca×P product were independent predictors of FGF23 levels. Conclusions FGF23 is frequently elevated in chronic hypoparathyroidism, indicating a disrupted phosphate metabolism, and its increase seems to be ineffective in promoting phosphate excretion, probably due to renal resistance mechanisms. Further studies are needed to clarify the role of FGF23 as a clinical biomarker, risk factor, and potential therapeutic target in this population.
Malagrinò et al. (Thu,) studied this question.